Who depends on Merck & Co.
Merck & Co. appears in 5 disclosed customer relationships between 2011 and 2024.
Get an email when Merck & Co.'s customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Suppliers that depend on Merck & Co.
Listed companies whose annual report names Merck & Co. as a customer worth 10% or more of their revenue. If Merck & Co. cuts orders or switches supplier, these are the companies that feel it.
Formerly disclosed
| Supplier | Its revenue from this company | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Rigel PharmaceuticalsRIGL | 89% | last FY 2011 | 1 year | FY 2011 · filed 4 Mar 2014 |
| ModernaMRNA | 61% | last FY 2019 | 4 years | FY 2019 · filed 25 Feb 2022 |
| CodexisCDXS | 29% | last FY 2018 | 7 years | FY 2018 · filed 1 Mar 2019 |
| ExelixisEXEL | 22% | last FY 2012 | 1 year | FY 2012 · filed 2 Mar 2015 |
| PersonalisPSNL | 11% | last FY 2022 | 3 years | FY 2022 · filed 28 Feb 2024 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API